ArticleJournal of kidney cancer and VHL2025
Mucinous Tubular and Spindle Cell Carcinoma: Case Report and Literature Review.
Article in Journal of kidney cancer and VHL, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A rare renal neoplasm: Case report of mucinous tubular and spindle cell carcinoma.Radiology case reports · 2026Article
- Mucinous Tubular and Spindle Cell Carcinoma of the Kidney: A Rare Renal Neoplasm-Case Report and Literature Review.Reports (MDPI) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare type of renal cell carcinoma (RCC) recognized as an independent entity in the latest WHO (World Health Organization) classification. We here report a case of a 51-year-old female patient with MTSCC, who presented with abdominal pain and left lower pole kidney lesion on the computed tomography scan. A robotic-assisted laparoscopic partial nephrectomy was performed. The diagnosis was confirmed on histopathological examination. MTSCC is rare and generally indolent. Either partial or radical nephrectomy is usually curative. The prognosis is usually favorable. However, occasionally, MTSCC could demonstrate aggressive features requiring systemic therapy. There are also several mimickers of MTSCC, which carry different prognostic and treatment profiles. Histological, immunohistochemical, and molecular genetic profile are useful in diagnosing the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.